Bio-rad Laboratories Stock News

https://www.investing.com/news/stock-market-news/biorad-laboratories-up-7-after-investor-day-2772756

WASHINGTON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Epigenetics Market finds that increasing cancer rates may further expediting market growth. Primarily driven by increasing research activity and funding for Epigenetics, the total Global Epigenetics Market is estimated to reach USD 3.0 Billion by 2028. The market stood at a revenue of USD 0.8 Billion in the year 2021, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 13.1%. Furthermore, the increasing personalized medication, and target therapy are also anticipated to augment the growth of the Global Epigenetics Market, states Vantage Market Research, in a report, titled " Epigenetics Market by Product (Instruments, Reagents & Kits, Others), by Application (Oncology, Autoimmune Diseases, Metabolic Diseases, CNS/Pain Diseases), by Technology (Methylation, Acetylation, Phosphorylation, Other Technologies), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

The recent market rout offers an opportune entry point to these seven robust stocks. These are good stocks to buy at their bottom now.

For the past half dozen years, investors couldn't care less about a company's balance sheet.

The average of price targets set by Wall Street analysts indicates a potential upside of 41.9% in Bio-Rad (BIO). While the effectiveness of this highly sought-after metric is questionable, the positiv

Strength in Life Sciences segment driven by a recovery in routine testing drove Bio-Rad (BIO) top line in the fourth quarter.

Bio Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q4 2021 Results - Earnings Call Transcript

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and year ended December 31, 2021. Fourth-quarter 2021 net sales were $732.8 million, a decrease of 7.2 percent compared to $789.8 million reported for the fourth quarter of 2020. On a currency-neutral basis, quarterly sales decreased 6.9 percent compared to the same period in 2020.

Bio-Rad (BIO) delivered earnings and revenue surprises of 11.85% and 0.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Investors are optimistic about Bio-Rad's (BIO) strong growth within Life Science and Clinical Diagnostics segments across all regions.

Bio Rad's (BIO) strength in its key product lines across major geographic regions buoys optimism.

PUNE, India, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Global Next Generation Sequencing (NGS) Market is growing with a CAGR of 17.1% in the forecast period of 2022 to 2029 and is expected to reach USD 29,307.13 Million by 2029. The most appropriate, exclusive, realistic, and admirable Next Generation Sequencing (NGS) Market Research Report is delivered with devotion depending upon the business needs. With the precise base year and the historic year, estimations and calculations are performed in this industry report. Market share analysis and key trend analysis are the key accomplishing factors in this market report. Report helps to recognize how the market is going to perform in the forecast years by giving information about market definition, classifications, applications, and engagements. DBMR team provides Next Generation Sequencing (NGS) Market research report with loyalty that is promising and the way in which expected. Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-next-generation-sequencing-ngs-market Key Companies operating in the Next Generation Sequencing (NGS) Market are: Agilent Technologies Inc Thermo Fisher Scientific Inc QIAGEN Illumina Inc Bio-Rad Laboratories Inc Roche Sequencing (A subsidiary of F.